Primary study · included by 1 review

High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis.

Zhao 2019 · Zhao Shankun, Xie Qiang, Yang Redian, et al. · Cancer management and research · 2019

Included by

Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.

Non-Cochrane · aetiology · 2026 · cited as Zhao 2019 · Table 1 (Included MA); References

Outcome this study informs	Pooled effect	Evidence	Certainty
Risk of bladder cancer in men With Benign prostatic hyperplasia vs Without Benign prostatic hyperplasia	RR 1.71	NR	GRADE not reported
Risk of bladder cancer in men With Benign prostatic hyperplasia vs Without Benign prostatic hyperplasia	RR 2.18	NR	GRADE not reported
Risk of bladder cancer in men With Benign prostatic hyperplasia vs Without Benign prostatic hyperplasia	RR 1.75 [1.38, 2.22]	NR	GRADE not reported
Risk of bladder cancer in men With Benign prostatic hyperplasia vs Without Benign prostatic hyperplasia	RR 1.51	NR	GRADE not reported
Risk of bladder cancer in men With Benign prostatic hyperplasia vs Without Benign prostatic hyperplasia	RR 1.95	NR	GRADE not reported
Secondary bladder cancer in men With radiotherapy for prostate cancer vs Without radiotherapy for prostate cancer	HR 1.60 [1.33, 1.92]	16 studies · 209494 participants	Very low
Risk of bladder cancer in men With Benign prostatic hyperplasia vs Without Benign prostatic hyperplasia	RR 1.71 [1.39, 2.11]	6 studies · 629896 participants	Low
Risk of bladder cancer in men With Benign prostatic hyperplasia vs Without Benign prostatic hyperplasia	RR 2.50	NR	GRADE not reported
Risk of bladder cancer in men With Benign prostatic hyperplasia vs Without Benign prostatic hyperplasia	RR 1.58	NR	GRADE not reported

1 including review in total.